Sarepta therapeutics inc（SRPT.US AI Earnings Summary）

The PMO franchise (Phosphorodiamidate Morpholino Oligomer) delivered its strongest single quarter in recent years, becoming the biggest surprise this quarter. Total net revenue for the three PMO products reached $240M, which is not only a 4% increase from the previous quarter ($231M) but also a 0.7% year-over-year increase ($239M). Among them, EXONDYS 51 reached $137M for the quarter, a year-over-year increase of approximately 8.4%. In the context of ELEVIDYS weighing down overall product revenue, the resilience of PMO is particularly prominent.

1. ELEVIDYS demand stabilizes, establishing a new baseline: CEO Mike Severino noted that third-quarter ELEVIDYS enrollment form activity was flat compared to the second quarter and higher than levels at the beginning of the year. Management views this as a "new baseline" for assessing subsequent commercial promotion effectiveness. ELEVIDYS net revenue this quarter was approximately $83M, consistent with the "lower than Q2" expectation given in the last earnings call, indicating the business has shifted from a freefall to bottom consolidation.

2. Full-year product revenue guidance lower limit raised by $50M: Based on the strong performance of PMO and the stability of ELEVIDYS, management raised the 2026 full-year total net product revenue guidance range from $1.2B–$1.3B to $1.25B–$1.3B. Simultaneously, the upper limit for full-year Non-GAAP R&D and SG&A combined expenses was narrowed from $850M to $825M, showing a two-way improvement of "raising the revenue floor and lowering the expense ceiling."

3. Continued Non-GAAP profitability, cash balance exceeds $1B: Non-GAAP operating income for the quarter was $22.9M, a significant improvement from the same period last year (Non-GAAP operating loss of $35.7M); the cash and investment balance reached $999M at quarter-end, an increase of approximately $45M from $954M at the end of 2025. CFO Ryan Wong pointed out that after excluding the $250M collaboration payment to Arrowhead, the core business has generated nearly $300M in cash year-to-date.

4. DM1 and FSHD Multiple Ascending Dose (MAD) study data to be revealed soon, Phase 3 preparations launched simultaneously: Management stated that MAD study data for SRP-1003 (DM1) and SRP-1001 (FSHD) is expected to be released "within weeks," and manufacturing and operational preparations for Phase 3 registration studies have been launched in parallel. CEO Severino emphasized that the accelerated approval path should remain open for both indications, noting that "whether accelerated approval can be obtained depends on the strength of the data, and we expect the data to be very strong."

5. DM1 nuclear splice correction data disclosed for the first time, showing nearly one-to-one knockdown effects inside and outside the nucleus: At the 2026 Oligonucleotide Therapeutics Society annual meeting, Sarepta announced that SRP-1003 achieved dose-dependent DMPK mRNA knockdown in both cytoplasm and nucleus compartments, with knockdown magnitude nearly one-to-one in both. It also confirmed correction of MBNL-dependent mis-splicing, meaning the drug indeed degrades pathogenic RNA within the nucleus.

6. First two-year functional data for ELEVIDYS in the 8 to 12-year-old group announced, strengthening treatment confidence for older patients: At the World Muscle Society annual meeting, Sarepta announced that after 8 to 12-year-old patients received ELEVIDYS treatment, they maintained quantifiable and clinically meaningful functional advantages in the North Star Ambulatory Assessment and timed function tests compared to an external control group over two years. This age group is a critical period for rapid functional decline in Duchenne patients; the data helps dispel physician concerns about treatment benefits for older patients.

7. ENVISION study terminated, non-ambulatory group strategy focuses on ENDEAVOR Cohort 8: Management announced they will not resume the ENVISION Phase 3 study, which has been suspended for over a year, citing operational and technical hurdles that are difficult to overcome after a long suspension. The path back to the non-ambulatory market now focuses on ENDEAVOR Cohort 8—the study assesses the safety of prophylactic sirolimus combined with ELEVIDYS. Enrollment is expected to complete by year-end, 12-week safety data will be obtained in 2026 Q1, followed by discussions with the FDA on a path to return to the non-ambulatory market.

8. MIS51ON study completes last patient last visit, EXONDYS 51 high-dose data to be revealed soon: The Phase 3 dose-ranging study (MIS51ON), a post-marketing commitment for EXONDYS 51, has reached the "last patient last visit" milestone; results will be announced after data cleanup. Additionally, supplemental New Drug Applications (sNDA) for AMONDYS 45 and VYONDYS 53 have been accepted by the FDA with a PDUFA goal date of February 28, 2027. If successfully converted to traditional approval, it will further solidify the long-term position of the PMO franchise.